vs
Apellis Pharmaceuticals, Inc.（APLS）与CarParts.com, Inc.（PRTS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是CarParts.com, Inc.的1.7倍（$199.9M vs $120.4M），CarParts.com, Inc.净利率更高（-9.6% vs -29.5%，领先19.9%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -9.8%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -14.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
GPC是一家总部位于美国佐治亚州亚特兰大的汽车与工业零部件分销商，1928年由弗雷泽兄弟创立，目前拥有约六万名员工。除美国本土市场外，公司业务还覆盖澳大拉西亚、比利时、加拿大、法国、德国、墨西哥、荷兰、波兰及英国，旗下拥有知名汽车零部件零售商NAPA Auto Parts和工业零部件分销商Motion。
APLS vs PRTS — 直观对比
营收规模更大
APLS
是对方的1.7倍
$120.4M
营收增速更快
APLS
高出3.9%
-9.8%
净利率更高
PRTS
高出19.9%
-29.5%
两年增速更快
APLS
近两年复合增速
-14.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $120.4M |
| 净利润 | $-59.0M | $-11.6M |
| 毛利率 | — | 33.2% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | -9.6% |
| 营收同比 | -5.9% | -9.8% |
| 净利润同比 | -62.2% | 25.0% |
| 每股收益（稀释后） | $-0.40 | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPRTS
| Q4 25 | $199.9M | $120.4M | ||
| Q3 25 | $458.6M | $127.8M | ||
| Q2 25 | $178.5M | $151.9M | ||
| Q1 25 | $166.8M | $147.4M | ||
| Q4 24 | $212.5M | $133.5M | ||
| Q3 24 | $196.8M | $144.8M | ||
| Q2 24 | $199.7M | $144.3M | ||
| Q1 24 | $172.3M | $166.3M |
净利润APLSPRTS
| Q4 25 | $-59.0M | $-11.6M | ||
| Q3 25 | $215.7M | $-10.9M | ||
| Q2 25 | $-42.2M | $-12.7M | ||
| Q1 25 | $-92.2M | $-15.3M | ||
| Q4 24 | $-36.4M | $-15.4M | ||
| Q3 24 | $-57.4M | $-10.0M | ||
| Q2 24 | $-37.7M | $-8.7M | ||
| Q1 24 | $-66.4M | $-6.5M |
毛利率APLSPRTS
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 33.1% | ||
| Q2 25 | — | 32.8% | ||
| Q1 25 | — | 32.1% | ||
| Q4 24 | — | 32.5% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 33.5% | ||
| Q1 24 | — | 32.4% |
营业利润率APLSPRTS
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -7.9% | ||
| Q2 25 | -18.6% | -8.2% | ||
| Q1 25 | -50.0% | -10.3% | ||
| Q4 24 | -12.3% | -11.6% | ||
| Q3 24 | -24.0% | -6.9% | ||
| Q2 24 | -14.7% | -6.0% | ||
| Q1 24 | -36.0% | -3.9% |
净利率APLSPRTS
| Q4 25 | -29.5% | -9.6% | ||
| Q3 25 | 47.0% | -8.5% | ||
| Q2 25 | -23.6% | -8.4% | ||
| Q1 25 | -55.3% | -10.4% | ||
| Q4 24 | -17.1% | -11.5% | ||
| Q3 24 | -29.2% | -6.9% | ||
| Q2 24 | -18.9% | -6.0% | ||
| Q1 24 | -38.5% | -3.9% |
每股收益（稀释后）APLSPRTS
| Q4 25 | $-0.40 | $-0.82 | ||
| Q3 25 | $1.67 | $-0.19 | ||
| Q2 25 | $-0.33 | $-0.23 | ||
| Q1 25 | $-0.74 | $-0.27 | ||
| Q4 24 | $-0.30 | $-0.28 | ||
| Q3 24 | $-0.46 | $-0.17 | ||
| Q2 24 | $-0.30 | $-0.15 | ||
| Q1 24 | $-0.54 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $25.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $53.5M |
| 总资产 | $1.1B | $184.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPRTS
| Q4 25 | $466.2M | $25.8M | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSPRTS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPRTS
| Q4 25 | $370.1M | $53.5M | ||
| Q3 25 | $401.2M | $64.2M | ||
| Q2 25 | $156.3M | $62.4M | ||
| Q1 25 | $164.2M | $72.8M | ||
| Q4 24 | $228.5M | $85.2M | ||
| Q3 24 | $237.1M | $97.2M | ||
| Q2 24 | $264.3M | $103.9M | ||
| Q1 24 | $266.7M | $109.2M |
总资产APLSPRTS
| Q4 25 | $1.1B | $184.9M | ||
| Q3 25 | $1.1B | $200.3M | ||
| Q2 25 | $821.4M | $189.6M | ||
| Q1 25 | $807.3M | $216.5M | ||
| Q4 24 | $885.1M | $210.6M | ||
| Q3 24 | $901.9M | $227.6M | ||
| Q2 24 | $904.5M | $238.0M | ||
| Q1 24 | $831.9M | $263.2M |
负债/权益比APLSPRTS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPRTS
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $-6.4M | ||
| Q2 25 | $4.4M | $-25.6M | ||
| Q1 25 | $-53.4M | $5.5M | ||
| Q4 24 | $19.4M | $1.8M | ||
| Q3 24 | $34.1M | $8.5M | ||
| Q2 24 | $-8.3M | $-3.6M | ||
| Q1 24 | $-133.0M | $3.7M |
自由现金流APLSPRTS
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $-8.3M | ||
| Q2 25 | $4.4M | $-27.9M | ||
| Q1 25 | $-53.4M | $3.4M | ||
| Q4 24 | $19.3M | $-631.0K | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | $-8.4M | $-10.8M | ||
| Q1 24 | $-133.3M | $-3.8M |
自由现金流率APLSPRTS
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | -6.5% | ||
| Q2 25 | 2.5% | -18.3% | ||
| Q1 25 | -32.0% | 2.3% | ||
| Q4 24 | 9.1% | -0.5% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | -4.2% | -7.5% | ||
| Q1 24 | -77.3% | -2.3% |
资本支出强度APLSPRTS
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | 0.0% | 4.9% | ||
| Q1 24 | 0.2% | 4.5% |
现金转化率APLSPRTS
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRTS
暂无分部数据
